Cross-sectional association of endogenous steroid hormone, sex hormone-binding globulin, and precursor steroid levels with hemostatic factor levels in postmenopausal women. 2017

L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
Department of Epidemiology, University of Washington, Seattle, WA, USA.

Essentials Endogenous hormone levels' influence on hemostatic factor levels is not fully characterized. We tested for associations of endogenous hormone with hemostatic factor levels in postmenopause. Estrone levels were inversely associated with the natural anticoagulant, protein S antigen. Dehydroepiandrosterone sulfate levels were inversely associated with thrombin generation. Background Oral use of exogenous estrogen/progestin alters hemostatic factor levels. The influence of endogenous hormones on these levels is incompletely characterized. Objectives Our study aimed to test whether, among postmenopausal women, high levels of estradiol (E2), estrone (E1), testosterone (T), dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), and androstenedione, and low levels of sex hormone-binding globulin (SHBG), are positively associated with measures of thrombin generation (TG), a normalized activated protein C sensitivity ratio (nAPCsr), and factor VII activity (FVIIc), and negatively associated with antithrombin activity (ATc) and total protein S antigen (PSAg). Methods This Heart and Vascular Health study cross-sectional analysis included 131 postmenopausal women without a prior venous thrombosis who were not currently using hormone therapy. Adjusted mean differences in TG, nAPCsr, FVIIc, ATc and PSAg levels associated with differences in hormone levels were estimated using multiple linear regression. We measured E2, E1, total T, DHEAS, DHEA and androstenedione levels by mass spectrometry, SHBG levels by immunoassay, and calculated the level of free T. Results One picogram per milliliter higher E1 levels were associated with 0.24% lower PSAg levels (95% Confidence Interval [CI]: -0.35, -0.12) and 1 μg mL-1 higher DHEAS levels were associated with 40.8 nm lower TG peak values (95% CI: -59.5, -22.2) and 140.7 nm×min lower TG endogenous thrombin potential (ETP) (95% CI: -212.1, -69.4). After multiple comparisons correction, there was no evidence for other associations. Conclusions As hypothesized, higher E1 levels were associated with lower levels of the natural anticoagulant PSAg. Contrary to hypotheses, higher DHEAS levels were associated with differences in TG peak and ETP that suggest less generation of thrombin.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011486 Protein C A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D003687 Dehydroepiandrosterone A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion. Dehydroisoandrosterone,Prasterone,5-Androsten-3-beta-hydroxy-17-one,5-Androsten-3-ol-17-one,Androstenolone,DHEA,Prasterone, 3 alpha-Isomer,5 Androsten 3 beta hydroxy 17 one,5 Androsten 3 ol 17 one,Prasterone, 3 alpha Isomer
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004970 Estrone An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women. Folliculin (Hormone),Estrone, (+-)-Isomer,Estrone, (8 alpha)-Isomer,Estrone, (9 beta)-Isomer,Estrovarin,Kestrone,Unigen,Wehgen
D005167 Factor VII Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa. Coagulation Factor VII,Proconvertin,Stable Factor,Blood Coagulation Factor VII,Factor 7,Factor Seven,Factor VII, Coagulation
D005260 Female Females
D006487 Hemostasis The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION. Hemostases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
March 2005, The Journal of clinical endocrinology and metabolism,
L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
November 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
August 2000, The Journal of clinical endocrinology and metabolism,
L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
November 2017, Clinical endocrinology,
L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
June 2017, Endocrine,
L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
June 2012, Clinical biochemistry,
L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
January 2016, Medicine,
L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
April 2017, Menopause (New York, N.Y.),
L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
December 2008, BMC medical genetics,
L B Harrington, and B T Marck, and K L Wiggins, and B McKnight, and S R Heckbert, and N F Woods, and A Z LaCroix, and M Blondon, and B M Psaty, and F R Rosendaal, and A M Matsumoto, and N L Smith
March 2001, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!